WHITEHOUSE STATION, N.J. A medical school dean has been appointed to the executive board of Merck & Co., the drug maker announced Wednesday.
Merck has appointed Michael Rosenblatt as EVP and chief medical officer, a position in which he will lead the company’s Global Center for Scientific Affairs and report directly to president and CEO Richard Clark.
“Merck’s fundamental mission is ensuring the well-being of patients worldwide, and Dr. Rosenblatt’s appointment reinforces our steadfast commitment to always remain focused on this goal,” Clark said. “Dr. Rosenblatt’s achievements in academia, clinical medicine and private industry are exceptional. With his nearly three decades of invaluable experience, I am pleased to welcome Dr. Rosenblatt to Merck’s executive team.”
Rosenblatt has served as dean of the Tufts University School of Medicine since 2003. Before that, he was a George R. Minot professor of medicine at Harvard Medical School and chief of the bone and mineral metabolism research division at Beth Israel Deaconess Medical Center, also serving as president of BIDMC from 1999 to 2001.